Exciting updates in the field of breast cancer were presented at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL. In this interview, Robert Coleman, MBBS, MD, FRCP, FRCPE, of the University of Sheffield, Sheffield, UK, discusses the results of the Phase III D-CARE study (NCT01077154), which investigated adjuvant denosumab in early breast cancer (EBC). He highlights the unsual primary endpoint of bone metastasis-free survival and the issues surrounding this. Dr Coleman also discusses the results of a similar study, which used a lower dose of denosumab (EudraCT: 2005-005275-15). Finally, he gives an insight into what the results of these studies mean for EBC treatment moving forwards.